Literature DB >> 23183430

Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology.

S-W Kim, S-S Yoon, R Suzuki, Y Matsuno, H G Yi, T Yoshida, M Imamura, A Wake, K Miura, M Hino, T Ishikawa, J S Kim, Y Maeda, J-J Lee, H J Kang, H S Lee, J-H Lee, K Izutsu, T Fukuda, C W Kim, T Yoshino, K Ohshima, S Nakamura, K Nagafuji, J Suzumiya, M Harada, C S Kim.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23183430     DOI： 10.1038/leu.2012.321

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

Authors:  Dai Chihara; Michelle A Fanale; Roberto N Miranda; Mansoor Noorani; Jason R Westin; Loretta J Nastoupil; Fredrick B Hagemeister; Luis E Fayad; Jorge E Romaguera; Felipe Samaniego; Francesco Turturro; Hun J Lee; Sattva S Neelapu; M Alma Rodriguez; Michael Wang; Nathan H Fowler; Richard E Davis; L Jeffrey Medeiros; Chitra Hosing; Yago L Nieto; Yasuhiro Oki
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 2.  Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

Authors:  M A Kharfan-Dabaja; N El-Jurdi; E Ayala; A S Kanate; B N Savani; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 3.  Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.

Authors:  Mitchell S Cairo; Auke Beishuizen
Journal:  Br J Haematol       Date:  2019-02-06       Impact factor: 6.998

4.  Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma.

Authors:  Hu Zhao; Yuan Chen; You-Ping Liao; Hai-Mei Chen; Qiu-Hong Yang; Yin Xiao; Jing Luo; Zhen-Zhen Chen; Lai Yi; Guo-Yu Hu
Journal:  Clin Exp Med       Date:  2022-03-03       Impact factor: 3.984

5.  Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.

Authors:  Yoshitaka Inoue; Nobuaki Nakano; Shigeo Fuji; Tetsuya Eto; Toshiro Kawakita; Youko Suehiro; Toshihiro Miyamoto; Yasushi Sawayama; Naoyuki Uchida; Tadakazu Kondo; Junya Kanda; Yoshiko Atsuta; Takahiro Fukuda; Makoto Yoshimitsu; Koji Kato
Journal:  Bone Marrow Transplant       Date:  2021-08-31       Impact factor: 5.483

Review 6.  Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Wen-Rong Huang; Dai-Hong Liu
Journal:  Chin Med J (Engl)       Date:  2018-09-05       Impact factor: 2.628

7.  Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.

Authors:  Akihiro Kitadate; Kentaro Narita; Kouta Fukumoto; Toshiki Terao; Takafumi Tsushima; Hiroki Kobayashi; Yoshiaki Abe; Daisuke Miura; Masami Takeuchi; Youichi Machida; Kosei Matsue
Journal:  Cancer Med       Date:  2020-06-18       Impact factor: 4.452

8.  Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas.

Authors:  Gu Zhenyang; Li Nainong; Wu Xiaoxiong; Wang Maihong; Fu Xiaorui; Wang Zhao; Ren Hanyun; Li Yuhang; Li Xiaofan; Wu Yamei; Liu Yao; Zhang Mingzhi; Wang Yini; Liu Daihong; Dong Yujun; Hu Liangding; Huang Wenrong
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

9.  Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.

Authors:  Ritsuko Nakai; Suguru Fukuhara; Akiko Miyagi Maeshima; Sung-Won Kim; Yuta Ito; Shunsuke Hatta; Tomotaka Suzuki; Sayako Yuda; Shinichi Makita; Wataru Munakata; Tatsuya Suzuki; Dai Maruyama; Koji Izutsu
Journal:  Clin Case Rep       Date:  2019-11-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.